Skip to main content

A. Hollebecque

BackgroundPancreatic ductal adenocarcinoma (PDAC) has a steadily increasing incidence and a poor prognosis, notably due to frequent and early resistance to standard-of-care treatments (SO...
06/25/2023
BackgroundPancreatic cancer is the 7th leading cause of cancer death worldwide and its incidence is on the rise. Chemotherapy with FOLFIRINOX is one of the metastatic first-line reference...
06/25/2023
BackgroundPeritoneal carcinomatosis (PC) is a common manifestation in gastro-intestinal (GI) cancers with highest incidence in gastric and colon cancer. Around 20 % of patients developp i...
06/25/2023
IDH1 and 2 (IDH1/2) are mutated in 10-15% of intrahepatic cholangiocarcinoma (CCA). The reversible IDH1 inhibitor ivosidenib is approved in 2L IDH1-mutant CCA. Cisplatin and gemcitabine (...
06/25/2023
Fibroblast growth factor receptor 2 ( FGFR2 ) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA). Futibatinib is a highly selective, cova...
06/25/2023
Background KRAS mutation is the most common molecular alteration in pancreatic adenocarcinoma (PDAC). However, 8-10% of patients harbor KRAS wild-type tumors (WT). The objectives of this...
06/29/2022
BackgroundAnal carcinoma (AC) is an uncommon malignancy; however, the incidence has been rising in the past years. Squamous cell carcinoma is the most frequent histological type, related ...
06/25/2023